Skip to search formSkip to main contentSkip to account menu

ZD4522

Known as: ZD 4522 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Rosuvastatin calciumrosuvastatin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Phase I Study of ZD4522 (Rosuvastatin), a New HMG-CoA Reductase Inhibitor-Evaluation of tolerance and Pharmacokinetics in Healthy Adult Male Volunteers after Single and Repeated Oral Administration-
Review
2002
Review
2002
Novel Statins: Pharmacological and Clinical Results
Rosuvastatin (ZD4522) and pitavastatin (NK-104) are novel HMG-CoA reductase inhibitors with a peculiar pharmacological profile… 
Review
2001
Review
2001
CLINICAL RATIONALE FOR ROSUVASTATIN, A POTENT NEW HMG‐COA REDUCTASE INHIBITOR
Coronary heart disease (CHD) is the leading cause of death worldwide, and effective treatment of hyperlipidaemia can prevent… 
2000
2000
Pharmacological properties of ZD4522 — A new HMG-CoA reductase inhibitor
2000
2000
Uptake of HMG-CoA reductase inhibitor ZD4522 into hepatocytes and distribution into liver and other tissues of the rat
2000
2000
Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia
2000
2000
New HMG-CoA reductase inhibitor ZD4522 lowers plasma lipids and VLDL production in APOE*3Leiden transgenic mice
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)